Medetomidine

Medetomidine

SCHEMBL787407

Cc1cccc(C(C)c2cnc[nH]2)c1C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRA2AADRA2BADRA2C

The experimentally established mechanism targets of Medetomidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ADRA2A known ✓ P08913 11/20 1.00
ADRA2B known ✓ P18089 11/20 1.00
ADRA2C known ✓ P18825 11/20 1.00
ADRA1D P25100 8/20 1.00
ADRA1A P35348 7/20 1.00
ADRA1B P35368 6/20 1.00
KCNH2 Q12809 1/20 1.00
TP53 P04637 1/20 1.00
CYP1A2 P05177 1/20 1.00
CYP3A4 P08684 1/20 1.00
CYP2D6 P10635 1/20 1.00
CYP2C9 P11712 1/20 1.00
TSHR P16473 1/20 1.00
CYP2C19 P33261 1/20 1.00
SLC6A2 P23975 1/20 0.97
HTR7 P34969 1/20 0.97

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dexmedetomidine SCHEMBL31048740 1.00 ADRA2A (1.00) ADRA2AADRA2BADRA2CADRA1DADRA1A
Medetomidine SCHEMBL29945090 1.00 ADRA2A (1.00) ADRA2AADRA2BADRA2CADRA1DADRA1A
Medetomidine SCHEMBL28305816 1.00 ADRA2A (1.00) ADRA2AADRA2BADRA2CADRA1DADRA1A
Dexmedetomidine SCHEMBL29363193 1.00 ADRA2A (1.00) ADRA2AADRA2BADRA2CADRA1DADRA1A
Dexmedetomidine SCHEMBL29546835 1.00 ADRA2A (1.00) ADRA2AADRA2BADRA2CADRA1DADRA1A
Dexmedetomidine SCHEMBL26433 1.00 ADRA2A (1.00) ADRA2AADRA2BADRA2CADRA1DADRA1A
Dexmedetomidine SCHEMBL30282088 0.98 ADRA2A (1.00) ADRA2AADRA2BADRA2CADRA1DADRA1A
Medetomidine SCHEMBL2202289 0.98 ADRA2A (1.00) ADRA2AADRA2BADRA2CADRA1DADRA1A
Dexmedetomidine SCHEMBL29833189 0.98 ADRA2A (1.00) ADRA2AADRA2BADRA2CADRA1DADRA1A
Dexmedetomidine SCHEMBL23498050 0.97 ADRA2A (0.94) ADRA2AADRA2BADRA2CADRA1DADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 358 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12378421-B2 Freeze-dried loaded aerogel particles with biocidal properties AEROGEL APS (DK) 2025-08-05 US claimed
EP-4363508-B1 FREEZE-DRIED LOADED AEROGEL PARTICLES WITH BIOCIDAL PROPERTIES AEROGEL APS (DK) 2025-07-23 EP claimed
US-20240270982-A1 FREEZE-DRIED LOADED AEROGEL PARTICLES WITH BIOCIDAL PROPERTIES AEROGEL APS (DK) 2024-08-15 US claimed
US-20230383129-A1 ANTIFOULING COMPOUNDS I-TECH AB (SE) 2023-11-30 US claimed
WO-2023275311-A1 PROCESS FOR FREEZE-DRIED LOADED AEROGEL PARTICLES WITH BIOCIDALPROPERTIES AEROGEL APS (DK) 2023-01-05 WO claimed
US-9290669-B2 Waterborne antifouling coating composition AKZO NOBEL COATINGS INTERNATIONAL B.V. (NL) 2016-03-22 US claimed
EP-2785804-B1 WATERBORNE ANTIFOULING COATING COMPOSITION AKZO NOBEL COATINGS INT BV (NL) 2015-11-18 EP claimed
US-20140318433-A1 WATERBORNE ANTIFOULING COATING COMPOSITION AKZO NOBEL COATINGS INTERNATIONAL B.V. (NL) 2014-10-30 US claimed
EP-2785804-A2 WATERBORNE ANTIFOULING COATING COMPOSITION Akzo Nobel Coatings International BV (NL) 2014-10-08 EP claimed
WO-2012150360-A2 WATERBORNE ANTIFOULING COATING COMPOSITION AKZO NOBEL COATINGS INTERNATIONAL B.V. (NL) 2012-11-08 WO claimed
EP-2079706-B1 METHOD FOR PREPARING MEDETOMIDINE AND ITS SALTS GRINDEKS JSC (LV) 2011-07-20 EP claimed
US-20250375423-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING 4-[1-(2,3-DIMETHYLPHENYL)ETHYL]-3H-IMIDAZOLE DERIVATIVES FOR TREATING RETINAL DISEASES ALLERGAN INC (US) 2025-12-11 US disclosed
US-20250325521-A1 USE OF SUBLINGUAL DEXMEDETOMIDINE FOR THE TREATMENT OF AGITATION BIOXCEL THERAPEUTICS INC (US) 2025-10-23 US disclosed
US-12378421-B2 Freeze-dried loaded aerogel particles with biocidal properties AEROGEL APS (DK) 2025-08-05 US disclosed
EP-4363508-B1 FREEZE-DRIED LOADED AEROGEL PARTICLES WITH BIOCIDAL PROPERTIES AEROGEL APS (DK) 2025-07-23 EP disclosed
WO-2007085556-A2 USE OF 4-IMIDAZOLE DERIVATIVES FOR CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2007-08-02 WO disclosed
US-20060223906-A1 Method and use of acidified modified polymers to bind biocides in paints I-TECH AB (SE) 2006-10-05 US disclosed
WO-2006096128-A1 METHOD AND USE OF NANOPARTICLES TO BIND BIOCIDES IN PAINTS I-TECH (SE) 2006-09-14 WO disclosed
WO-2006096129-A1 METHOD AND USE OF ACIDIFIED MODIFIED POLYMERS TO BIND BIOCIDES IN PAINTS I-TECH (SE) 2006-09-14 WO disclosed
US-20060201379-A1 Method and use of nanoparticles to bind biocides in paints I-TECH AB (SE) 2006-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250375423-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING 4-[1-(2,3-DIMETHYLPHENYL)ETHYL]-3H-IMIDAZOLE DERIVATIVES FOR TREATING RETINAL DISEASES ALDH1A2, PDE6D, NR2E3 ADRA2A 445/4885ADRA2B 255/4885ADRA2C 308/4885
US-12378421-B2 Freeze-dried loaded aerogel particles with biocidal properties LCT, SOST, LBR ADRA2A 2103/4885ADRA2B 2803/4885ADRA2C 3582/4885
US-20240270982-A1 FREEZE-DRIED LOADED AEROGEL PARTICLES WITH BIOCIDAL PROPERTIES LCT, SOST, LBR ADRA2A 2103/4885ADRA2B 2803/4885ADRA2C 3582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.